Belite Bio (NASDAQ:BLTE – Get Free Report) issued its earnings results on Monday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02), Zacks reports.
Belite Bio Trading Down 3.0 %
BLTE opened at $67.44 on Monday. The firm’s fifty day simple moving average is $58.40 and its 200 day simple moving average is $60.33. The stock has a market capitalization of $2.15 billion, a P/E ratio of -60.76 and a beta of -1.54. Belite Bio has a 12 month low of $31.01 and a 12 month high of $86.53.
Wall Street Analysts Forecast Growth
Separately, Benchmark lifted their price objective on Belite Bio from $57.00 to $79.00 and gave the company a “buy” rating in a report on Tuesday, January 21st.
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
Recommended Stories
- Five stocks we like better than Belite Bio
- Transportation Stocks Investing
- Maximize Your Dividends With These 3 High-Yield ETFs
- Profitably Trade Stocks at 52-Week Highs
- 3 Undervalued Stocks Poised for a Strong Comeback
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Meta Platforms: Can LLaMA Drive Long-Term Stock Growth?
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
